1Sliwa K,Hilfiker-Kleiner D,Petrie M C. Current State of Knowledge on a Etiology,Diagnosis,Management,and Therapy of Peripartum Cardiomyopathy:a Position Statement from the Heart Failure Association of the European Society of Cardiology Working Group on Peripartum Cardiomyopathy[J].{H}European Journal of heart failure,2010,(08):767-778.
4[3]Felker GM,Jaeger CJ,Klodas E,et al.Myocarditis and long-term survival in peripartum cardiomyopathy[J].Am Heart J,2000,140(5):785-791.
5[4]Felkner GM,Thompson RE,Hare JM,et al.Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy[J].N Engl J Med,2000,342(15):1077-1084.
6[5]Klintschar M,Schwaiger P,Mannweiler S,et al.Evidence of fetal microchimerism in Hashimoto's thyroiditis[J].J Clin Endocrinol Metab,2001,86(6):2494-2498.
7[6]Johnson KL,Nelson JL,Furst DE.Fetal cell microchimerism in tissue from multiple sites in women with systemic sclerosis[J].Arthritis Rheum,2001,44(8):1848-1854.
8[7]Sliwa K,Skudicky D,Bergemann A,et al.Peripartum cardiomyopathy:analysis of clinical outcome,left ventrieular function,plasma levels of cytokines and Fas/APO-1[J].J Am Coil Cardiol,2000,35(3):701-705.
9[8]Warraich RS,Sliwa K,Damasceno A,et al.Impact of oregnancyrelated heart failure on humoral immunity:chinieal relevance of G3 subclass immunoglobulins in peripartum cardiomyopathy[J].Am Heart J,2005,150(2):263-269.
10[9]Warraich RS,Young JB,Sestier F,et al.Clinical and prognostic relevance of lg-G3 reactivity in heart failure:a substudv of vasozen's immune modulation therapy in patients with chronic heart failure[J].J Am Coil Cardiol,2004,43(5):226A.
